Fermer le menu

Current drug discovery tools are inadequate to address MDR/XDR pathogens, requiring development of alternative strategies to be able to explore and target these problematic pathogens.


IMPACT2AMR aims to deliver a single research platform that is composed of three independent sub-components, which will be used to expedite development of antimicrobials and novel anti-virulence drugs.


Clients can select all three or individual components
to develop targeted solutions against the KAPE-pathogens:


1. Novel in vitro methods

The In Vitro Platform provides novel in vitro methods allowing fast genetic manipulation (knock-in / -out, site directed target mutagenesis) of any MDR/XDR clinical isolate of the KAPE pathogen group. This platform will be used to generate bioluminescent clinical isolates for the other platforms. BioVersys will market bioluminescent clinical strains and provide on-demand bacterial genome engineering to customers.

2. Alternative in vivo model host

The TruLarv Platform uses an alternative in vivo model host, combined with the bioluminescent strains delivered by the In Vitro Platform, to track intracellular pathogens and obtain an in vivo proof-of-concept (PoC) in Galleria mellonella larvae, enabling this system to be used for cost effective, high-throughput antimicrobial compound screening. The TruLarv™ Platform using the same bioluminescent strains as the In Vivo Platform, can be used as a filter to reduce the amount of test compounds finally validated in the murine infection models. BioSystems Technology will market research grade TruLarv™ G. mellonella compatible with high throughput imaging systems for cost effective in vivo screening of important clinical bacterial and fungal isolates, antimicrobial efficacy and compound toxicity.

3. Real-life in vivo PoC

The In Vivo Platform uses relevant murine infection models, combined with the bioluminescent strains delivered by the In Vitro Platform to obtain a real-life in vivo PoC. These infection models can be used to evaluate the efficacy of novel drug candidates and to explore potential new targets for antibacterial/antivirulence therapy.

The following infection mouse models with bioluminescent pathogens will be developed by Voxcan and made available to customers for preclinical efficacy studies:

Infection model – bioluminescent pathogens
Pneumonia: A. baumannii and K. pneumoniae
UTI: E. coli and K. pneumoniae
Sepsis: E.coli and K. pneumoniae